WolverHeme Happy Hour

In this episode, Tycel Phillips, MD joins Anthony and Bernie to discuss updates in Mantle Cell Lymphoma, including the TRIANGLE study and the recently published results of glofitamab in R/R MCL.

TRIANGLE: https://pubmed.ncbi.nlm.nih.gov/38705160/

Glofitamab: https://pubmed.ncbi.nlm.nih.gov/39365960/

In this episode, Anthony and Bernie discuss the recently reported APOLLO trial in high-risk APL and debate whether this should represent the new standard of care in this population. We also review key practical considerations for the treatment of APL patients, including side effect management and treatment of APL in unique clinical scenarios.

APOLLO: https://library.ehaweb.org/eha/2024/eha2024-congress/422206/uwe.platzbecker.first.results.of.the.apollo.trial.a.randomized.phase.iii.study.html

In this episode, Bernie and Anthony review the full history of APL treatment, in preparation for the upcoming plenary presentation of the APOLLO study THIS WEEKEND at EHA 2024!

How did we get to our current standard of care in APL? How and why did the PETHEMA, GIMEMA, UK MRC, and other cooperative group regimens evolve over time into what they are today?

And importantly, is the APOLLO control arm (no arsenic!), ok? Tune in to find out!

In this episode, Anthony and Bernie are joined by Multiple Myeloma expert Dr. Manni Mohyuddin, to discuss the recent FDA approval updates of CAR-T in this disease state. We also discuss the hotly debated topic of MRD as a surrogate endpoint for accelerated approval in Myeloma.

In this episode, Anthony and Bernie review the most impactful and interesting ALL abstracts at the 2023 ASH Annual Meeting. We dive into the nelarabine abstracts, calaspargase (cal-peg), and the evolution of the treatment of Ph+ ALL!

Abstracts discussed:

OMG! In this extra fun holiday episode, we are joined by lymphoma experts Tycel Phillips and Aaron Goodman to review the most impactful and controversial lymphoma abstracts from ASH! Stay tuned for a lively discussion!

Abstracts Discussed!

In this episode, Anthony and Bernie discuss the AML abstracts at ASH that we found most intriguing and controversial!

Abstracts:

In this episode, Anthony and Bernie are joined by two very special guests - Dr. Aaron "Papa Heme" Goodman and Dr. Manni "Myeloma Man" Mohyuddin - to discuss the most interesting myeloma abstracts at the upcoming 2023 ASH meeting! Will any of these change practice? Listen to find out!

Abstracts Discussed:

In the second portion of our two part-series on AML maintenance, Anthony and Bernie delve into the studies of post-transplant FLT3 inhibitor maintenance. We discuss the controversial MORPHO study of gilteritinib and whether these results will change practice!

In the first of a two part-series, Anthony and Bernie dive into the data surrounding maintenance therapies in AML. This episode focuses on maintenance therapy for patients ineligible for transplant, with a focus on oral azacitidine and the controversial QUAZAR study.

Key References: